Industry news
Transfer of products from Actelion to Idorsia Ltd
The products to transfer to Idorsia Ltd following the acquisition of Actelion by Johnson & Johnson are aprocitentan (ACT 132577) for resistant hypertension( J&J retain an option to acquire this product), ACT 541468 for insomnia, clazosentan for vasospasm, and cenerimod for SLE which are all in Phase II development. Additionally to be transferred are lucerastat for Fabry disease which is in Phase 1b and ACT 246475 for acute coronary syndrome, ACT 774312 for asthma and allergy, ACT 539313 for anxiety and ACT 709478 for epilepsy which are all in Phase 1.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
